|

UBX-303061 Clinical Trials

1 actively recruiting trial across 1 location

Pipeline

Phase 1: 1

Top Sponsors

  • Ubix Therapeutics, Inc.1

Indications

  • Relapsed/Refractory B-cell Malignancies1
  • Cancer1

Ann Arbor, Michigan1 trial

UBX-303061 in Subjects With Relapsed/Refractory B-Cell Malignancies

University of Michigan

Phase 1

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.